Order Online! Now! Get your $50 coupon for online order.
Order Online! Now! Get your $50 coupon for online order.
Our limited edition HOLIDAYS LLAMA is here! Place any order now to recieve one!
Earn Loyalty Rewards! Up to $155 Amazon Gift Card
Time Limited Offer: Welcome Gift for New Customers !
Time Limited Offer: Welcome Gift for New Customers !
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CO3-H82E8 | Human | Biotinylated Human Complement C3 Protein, His,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
CO3-C52H5 | Cynomolgus | Cynomolgus Complement C3 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
CO3-M52H4 | Mouse | Mouse Complement C3 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
|
CO3-H52H3 | Human | Human Complement C3 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
Immobilized Cynomolgus Complement C3, His Tag (Cat. No. CO3-C52H5) at 1 μg/mL (100 μL/well) can bind Human Anti-C3,Human IgG1 Human Kappa with a linear range of 0.2-8 ng/mL (QC tested).
The purity of Biotinylated Human Complement C3, His,Avitag (Cat. No. CO3-H82E8) is more than 85% and the molecular weight of this protein is around 165-200 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Pegcetacoplan | APL-2 | Approved | Apellis Pharmaceuticals Inc | Aspaveli, Empaveli | United States | Hemoglobinuria, Paroxysmal | Apellis Pharmaceuticals Inc | 2021-05-14 | Motor Neuron Disease; Rejection of renal transplantation; Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Glomerulonephritis, Membranous; Lupus Nephritis; Thrombotic Microangiopathies; Glomerulonephritis, Membranoproliferative; Anemia, Hemolytic, Autoimmune; Geographic Atrophy; Amyotrophic Lateral Sclerosis; Glomerulonephritis; Macular Degeneration | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
NGM-621 | NGM-621 | Phase 2 Clinical | Ngm Biopharmaceuticals Inc | Coronavirus Disease 2019 (COVID-19); Geographic Atrophy | Details |
Efdamrofusp alfa | IBI-302 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration | Details |
Compstatin 40 | AMY-101 | Phase 2 Clinical | University Of Pennsylvania | Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Gingivitis | Details |
ARO-C3 | ARO-C3; ARO-C-3 | Phase 1 Clinical | Arrowhead Pharmaceuticals Inc | Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal; Glomerulonephritis | Details |
CG-001 | CG-001 | Phase 1 Clinical | Chengdu Konjin Co Ltd | Hemoglobinuria, Paroxysmal; Autoimmune Diseases | Details |
ALXN-1820 | ALXN-1820 | Phase 2 Clinical | Alexion Pharmaceuticals Inc | Anemia, Sickle Cell | Details |
This web search service is supported by Google Inc.